Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Could venetoclax combined with bortezomib and dexamethasone help to treat patients with relapsed/refractory multiple myeloma?

Could venetoclax combined with bortezomib and dexamethasone help to treat patients with relapsed/refractory multiple myeloma?

Posted by on Nov 28, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated whether giving patients with relapsed/resistant multiple myeloma (MM) venetoclax (Venclexta), in combination with bortezomib (Velcade) and dexamethasone (Ozurdex), will improve patient survival. This study showed that these patients would benefit from this treatment combination. Some background...

Read More

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

Comparing the outcomes of carfilzomib once-weekly vs twice-weely in patients with relapsed/refractory multiple myeloma

Posted by on Oct 29, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study compared outcomes of once-weekly (OW) versus twice-weekly (TW) carfilzomib (Kyprolis) plus dexamethasone (Decadron) in Japanese patients with relapsed/refractory (RR) multiple myeloma (MM). The authors found that the OW dosage improved overall response rate (ORR) compared to TW in such patients. Some background RR-MM...

Read More

Effects of ixazomib maintenance in patients with newly diagnosed multiple myeloma who are not undergoing autologous stem cell transplantation

Effects of ixazomib maintenance in patients with newly diagnosed multiple myeloma who are not undergoing autologous stem cell transplantation

Posted by on Oct 24, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated outcomes of ixazomib (Ninlaro) as a maintenance therapy in patients with newly diagnosed multiple myeloma (MM) not undergoing autologous stem cell transplantation (ASCT). The main finding was that ixazomib maintenance safely improved progression-free survival (PFS) in such patients.   Some background...

Read More

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Elotuzumab, lanalidomide and dexamethasone increases overall survival of patients with relapsed or refractory multiple myeloma.

Posted by on Oct 10, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the effectiveness and safety of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone (Decadron) in relapsed or refractory (unresponsive) multiple myeloma (MM). The authors found that there was an improved survival in these patients in the long-term. Some...

Read More

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Posted by on Sep 20, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...

Read More

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...

Read More

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the use of daratumumab (Darzalex) plus bortezomib (Velcade)/dexamethasone (Dexasone) or D-Vd versus bortezomib/dexamethasone (Vd) alone as a treatment for patients with high-risk multiple myeloma (MM). The authors found that D-Vd was effective and showed good tolerability...

Read More

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Posted by on Aug 30, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study is being carried out to examine whether KRD including carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Decadron) with or without daratumumab (Darzalex) is safe and effective in the treatment of multiple myeloma (MM). The main outcome to be measured is the measurable residual...

Read More

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Posted by on Jul 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated outcomes of the combination of carfilzomib (Kyprolis; K), dexamethasone (Decadron; d), and daratumumab (Darzalex; D) in patients with relapsed or refractory (r/r) multiple myeloma (MM). The authors found that KdD was safe and effective to improve progression-free survival (PFS) in such patients compared to...

Read More

COVID-19 with Cancer

COVID-19 with Cancer

Posted by on Jul 31, 2020 in Blog, Breast cancer, Colorectal cancer, Coronavirus / COVID-19, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...

Read More